Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Major study finds opioid addiction raises dementia risk by 56% compared with non‑users.

Mature and old people laughing at a shared meal

Individuals addicted to opioids have a 56% higher risk of developing dementia than non-users, according to a study led by researchers at the Nuffield Department of Population Health and the Department of Psychiatry, University of Oxford. The findings are published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

Opioids are a class of natural, semi-synthetic, and synthetic drugs that include prescription pain medications such as oxycodone and fentanyl, and illegal drugs such as heroin. They work by binding to opioid receptors in the brain and spinal cord, blocking pain signals and producing feelings of euphoria.

Over-prescribing of opioids in the 1990s, particularly in the United States and Canada, contributed to a wave of opioid misuse and overdose deaths that led the US Department of Health and Human Services to declare a public health emergency in 2017. More recently, the opioid crisis has been driven by illegally manufactured fentanyl.

Senior Clinical Researcher at the Nuffield Department of Population Health and lead author of the study, Dr Anya Topiwala said ‘While the short-term effects of opioids are well known, our findings show that opioid use disorder may also have important long-term consequences for brain health, including a higher risk of dementia. Using large-scale data and genetic methods, we found evidence suggesting this link may be causal, pointing to the direct impact of opioid exposure rather than underlying genetic risk.’ 

Read the full story on the Nuffield Department of Population Health website.

Similar stories

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies from the University of Oxford, Queen Mary University of London and the University of Bristol, have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Oxford medical student takes AI safety message to the Palace of Versailles

Oxford medical student Julian Shellard has presented at an international workshop on the future of Artificial Intelligence (AI) at the Palace of Versailles in Paris, highlighting the important role medical students can play in global conversations on shaping the future of science and medicine.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group at the MRC Weatherall Institute of Molecular Medicine, have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Dunn School publishes new children’s book to mark centenary

The collaboration with Oxford University Press brings the story of the development of Penicillin to a new audience